Request Demo
Last update 08 May 2025
PEGylated thrombopoietin(Chongqing Paijin Biotechnology Co Ltd)
Last update 08 May 2025
Overview
Basic Info
Drug Type Colony-stimulating factors |
Synonyms + [3] |
Action agonists, inhibitors |
Mechanism EPO receptor agonists(Erythropoietin receptor agonists), TPO receptor inhibitors(Thrombopoietin receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
8
Clinical Trials associated with PEGylated thrombopoietin(Chongqing Paijin Biotechnology Co Ltd)NCT06880081
A Phase 1b, Open-label, Single-arm, Dose-escalation Study of PN20 in Patients with Primary Immune Thrombocytopenia (ITP)
CTR20250022
评价注射用聚乙二醇化促血小板生成肽(PN20)单次给药在成人原发免疫性血小板减少症患者的研究
[Translation] A study evaluating the efficacy of a single dose of pegylated thrombopoietic peptide for injection (PN20) in adult patients with primary immune thrombocytopenia
NCT06521931
A Single-arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Patients With Lymphoma or Solid Tumor
100 Clinical Results associated with PEGylated thrombopoietin(Chongqing Paijin Biotechnology Co Ltd)
Login to view more data
100 Translational Medicine associated with PEGylated thrombopoietin(Chongqing Paijin Biotechnology Co Ltd)
Login to view more data
100 Patents (Medical) associated with PEGylated thrombopoietin(Chongqing Paijin Biotechnology Co Ltd)
Login to view more data
100 Deals associated with PEGylated thrombopoietin(Chongqing Paijin Biotechnology Co Ltd)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Thrombocytopenia | Phase 2 | China | - | |
| Chronic liver disease | Phase 1 | China | 15 Apr 2025 | |
| Lymphoma | Phase 1 | China | 06 Dec 2023 | |
| Solid tumor | Phase 1 | China | 06 Dec 2023 | |
| Purpura, Thrombocytopenic, Idiopathic | Phase 1 | China | 16 Jun 2022 | |
| Chronic thrombocytopenia | IND Approval | China | 20 Jan 2025 | |
| Primary thrombocytopenia | IND Approval | China | 04 Jun 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free